Form 4: Arrowhead Pharmaceuticals CEO Christopher Anzalone Sells Shares to Cover Taxes

Arrowhead Pharmaceuticals CEO Christopher Anzalone sold shares of common stock between April 9th and April 11th, 2025, to cover taxes associated with the vesting of restricted stock awards.

Summary

• Christopher Anzalone, CEO of Arrowhead Pharmaceuticals, sold shares of the company's common stock between April 9th and April 11th, 2025.
• The sales were executed to cover taxes associated with the vesting of restricted stock awards.
• On April 9th, 2025, he sold 35,305 shares at a weighted average price of $9.93, 3,400 shares at a weighted average price of $10.75 and 1,617 shares at a weighted average price of $11.76.
• On April 10th, 2025, he sold 50,000 shares at $10.87.
• On April 11th, 2025, he sold 50,800 shares at $11.49.
• Following these transactions, Anzalone directly owns 3,921,255 shares of Arrowhead Pharmaceuticals, which includes shares underlying Restricted Stock Units subject to vesting conditions.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating insider trading activity. The sentiment is neutral as it simply reports transactions without expressing any positive or negative views about the company's prospects.

Industry Context

Insider sales are a common occurrence, especially when executives exercise stock options or restricted stock units. It is important to consider the context of the sale, such as the executive's overall holdings and the company's performance, before drawing conclusions.

Stakeholder Impact

• The sale of shares by the CEO could be perceived negatively by some shareholders, potentially creating short-term selling pressure.
• However, the explanation that the sales were to cover taxes associated with vesting may mitigate concerns.

Key Dates

Keywords

Arrowhead Pharmaceuticals, ARWR, Christopher Anzalone, stock sale, Form 4, CEO, insider trading, restricted stock units, vesting, taxes